DPIV Drug Analysis Report 2018 - ResearchAndMarkets.com

DUBLIN--()--The "Drug Analysis: DPIV" drug pipelines has been added to ResearchAndMarkets.com's offering.

DPIV is a tetravalent, AS03B-adjuvanted, purified formalin-inactivated dengue virus vaccine being developed by GlaxoSmithKline in collaboration with the US Walter Reed Army Institute of Research and the Oswaldo Cruz Foundation in Brazil. The four dengue virus serotypes (DEN-1/2/3/4) are grown in Vero cells before being concentrated, purified, and formalin-inactivated.

DPIV is currently in Phase I/II development in the US and Puerto Rico only, but will likely be assessed in Phase II proof-of-concept studies in the same dengue-endemic markets as Dengvaxia (tetravalent live-attenuated chimeric vaccine; Sanofi Pasteur) and TAK-003 (tetravalent live-attenuated chimeric vaccine; Takeda).

Having shelved the development of its own live-attenuated vaccine (LAV), GlaxoSmithKline has decided to pursue the approval of an inactivated vaccine because of the reduced likelihood of serotype interference, and the potential for a more compact dosing schedule. As an anticipated late entrant into the dengue vaccine market, DPIV's commercial success will be dependent on its ability to provide at least non-inferior protection to the tetravalent live-attenuated chimeric vaccines Dengvaxia and TAK-003 with a shorter two-dose schedule, either as a standalone agent, or as part of a heterologous prime-boost strategy with an LAV.

DPIV's more convenient dosing schedule could also make it an attractive option for travelers and the military, although the vaccine is expected to face competition in these segments from Merck & Co's V180 (adjuvanted, tetravalent DEN-80E subunit vaccine), which is also being assessed in a heterologous prime-boost strategy with TetraVax-DV (tetravalent live-attenuated chimeric vaccine; Biological E/Panacea Biotec/Butantan Institute/Merck & Co/Vabiotech).

Key Topics Covered:

Product Profiles

DPIV: Dengue vaccines

List of Figures

Figure 1: DPIV for dengue fever - SWOT analysis

List of Tables

Table 1: DPIV drug profile

Table 2: DPIV completed Phase I studies in dengue fever

Table 3: DPIV ongoing studies in dengue fever

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/5xgbp4/dpiv_drug?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Vaccines

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Vaccines